Asset Details
Do you wish to reserve the book?
Nirsevimab to reduce infant morbidity from respiratory syncytial virus
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Nirsevimab to reduce infant morbidity from respiratory syncytial virus
Do you wish to request the book?
Nirsevimab to reduce infant morbidity from respiratory syncytial virus
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Nirsevimab to reduce infant morbidity from respiratory syncytial virus
2024
Overview
Respiratory syncytial virus (RSV) is a common virus that can cause serious infections in newborns and infants, especially those with certain risk factors. Until recently, the only intervention available to prevent RSV in infants was palivizumab, but its use has been limited. However, a new intervention called nirsevimab has been approved in Canada. Nirsevimab is a long-acting monoclonal antibody that prevents RSV infection by blocking the virus's entry. It has been shown to be highly effective in reducing the risk of RSV infection, hospital admissions, and severe RSV disease. Nirsevimab is safe and well-tolerated, with minimal side effects. It is recommended for infants up to 24 months of age, particularly those at high risk. Nirsevimab programs are being implemented in various countries, and its use is expected to replace palivizumab for high-risk infants. However, the availability and implementation of nirsevimab programs vary across different regions.
Publisher
CMA Impact Inc,CMA Impact, Inc
Subject
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Antiviral Agents - therapeutic use
/ Babies
/ Diseases
/ Humans
/ Infant
/ Infants
/ Palivizumab - therapeutic use
/ Practice
/ Respiratory syncytial virus infection
/ Respiratory Syncytial Virus Infections - epidemiology
/ Respiratory Syncytial Virus Infections - prevention & control
/ Vaccines
/ Winter
